Associated Papers
Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report.
Arthur C et al.
Npj Precision Oncology, 2026
GUK1 activation is a metabolic liability in lung cancer.
Schneider JL et al.
Cell, 2025
Germline functional variants contribute to somatic mutation and outcomes in neuroblastoma.
Seo ES et al.
Nature Communications, 2024
Germline pathogenic variants in 786 neuroblastoma patients.
Kim J et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastoma.
Bonfiglio F et al.
Ebiomedicine, 2023
Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling.
Aboualizadeh F et al.
Journal of Molecular Biology, 2021
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
Uçkun E et al.
Journal of Molecular Biology, 2021
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase.
Johnson TW et al.
Acs Medicinal Chemistry Letters, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Science, 2017
Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.
Sami N et al.
Molecular Neurobiology, 2017
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J et al.
Oncotarget, 2017
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
Mossé YP
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC et al.
Cancer Cell, 2014
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D et al.
Disease Models & Mechanisms, 2013
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
Schönherr C et al.
The Biochemical Journal, 2011
Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ et al.
Pathology, Research and Practice, 2011
Emerging importance of ALK in neuroblastoma.
Azarova AM et al.
Seminars in Cancer Biology, 2011
The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.
Schönherr C et al.
Translational Oncology, 2011
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC et al.
The Biochemical Journal, 2010
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT et al.
Biochemistry, 2010
Genetics and genomics of neuroblastoma.
Capasso M et al.
Cancer Treatment and Research, 2010
Anaplastic lymphoma kinase: signalling in development and disease.
Palmer RH et al.
The Biochemical Journal, 2009
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR et al.
Expert Review of Anticancer Therapy, 2009
Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP et al.
Nature, 2008